Personalized RT strategies are moving locally advanced NSCLC beyond the PACIFIC template
Modern LA-NSCLC RT is shifting toward selective escalation, de-escalation and organ sparing, increasingly guided by patient risk and tumor biology.
Tag
chemoradiotherapy
Omitting CTV reduced toxicity without compromising outcomes in limited-stage SCLC
After matching 530 patients, CTV omission preserved survival and recurrence patterns while substantially reducing pneumonitis and esophagitis.
Total laryngectomy improved local control over chemoradiotherapy in selected advanced laryngeal cancer
Surgery provided substantially better local control in T3–T4a N0–N1 laryngeal cancer, while disease-specific survival remained similar and CRT preserved laryngeal function in 79%.
HYPOCON tests biphasic chemoradiotherapy to target hypoxia in head and neck cancer
HYPOCON will test 40 Gy/20 fractions followed by 15 Gy/3 against 55 Gy/20, both with concurrent cisplatin.
Daily low-dose cisplatin chemoradiotherapy remained feasible in older stage III NSCLC
Patients >70 receiving 66 Gy with daily low-dose cisplatin had survival and severe toxicity similar to younger patients in this retrospective cohort.
Older patients maintained recurrence control after definitive anal cancer chemoradiotherapy
Patients aged ≥70 had similar recurrence outcomes after definitive chemoradiotherapy despite inferior overall survival and greater competing mortality.
Neoadjuvant chemoradiotherapy was associated with better survival in locally advanced gastric cancer
Neoadjuvant chemoradiotherapy achieved 26.5% pathological complete response and 80.4% five-year survival, outperforming chemotherapy-based strategies in this retrospective cohort.
Long-course chemoradiotherapy improved early organ preservation in STAR-TREC
Twelve-month TME-free survival was 78.5% with long-course chemoradiotherapy versus 60.6% with short-course radiotherapy in early rectal cancer.
Age and comorbidity identified poor prognosis in elderly patients receiving esophageal chemoradiotherapy
Patients aged ≥75 years with CIRS-G ≥7 had median overall survival of 16 months after definitive chemoradiotherapy.
Induction TPF did not improve three-year PFS over adjuvant PF in locally advanced NPC
Three-year PFS was 79.0% with induction TPF versus 74.5% with adjuvant PF, with substantially different toxicity profiles.
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
Iridium-192 boost improved progression-free survival in unresectable hilar cholangiocarcinoma
An iridium-192 boost increased median progression-free survival from 8.6 to 11.2 months, without a significant overall-survival improvement.
Twice-daily radiotherapy was associated with longer survival in younger limited-stage small cell lung cancer
Among patients under 70, twice-daily chemoradiotherapy was associated with 36.0 versus 22.2 months median survival, without higher acute toxicity.
Carboplatin-paclitaxel showed comparable outcomes in cisplatin-ineligible head and neck cancer
Retrospective outcomes with carboplatin-paclitaxel were not significantly different from cisplatin, supporting its use when cisplatin is contraindicated.
Escalating esophageal chemoradiotherapy from 50.4 to 60 Gy provided no benefit
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.